Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$23.11 +1.4%	$21.37	$15.47 ▼ $36.37	$780.06M	1.26	215,056 shs	928,851 shs
BCAX Bicara Therapeutics	$9.51 +3.6%	$12.25	$7.80 ▼ $28.09	$500.64M	N/A	581,102 shs	653,458 shs
CDXC ChromaDex		$6.16	$2.31 ▼ $9.18	$611.50M	2.21	827,665 shs	554,788 shs
MOLN Molecular Partners	$3.60 -7.6%	$3.88	$3.36 ▼ $12.22	$144.54M	1.11	15,162 shs	3,191 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	+1.36%	-7.49%	+13.28%	+26.42%	+29.40%
BCAX Bicara Therapeutics	+3.59%	-1.65%	+2.59%	-27.40%	+950,999,900.00%
CDXC ChromaDex	0.00%	0.00%	0.00%	0.00%	+208.43%
MOLN Molecular Partners	+0.42%	-4.92%	-11.32%	-16.40%	-50.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVBP ArriVent BioPharma	1.2409 of 5 stars	3.6	0.0	0.0	0.0	2.0	0.8	0.0
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CDXC ChromaDex	2.7108 of 5 stars	3.5	0.0	0.0	4.0	0.6	0.0	1.9
MOLN Molecular Partners	2.3228 of 5 stars	3.8	5.0	0.0	0.0	0.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	3.14	Buy	$40.00	73.09% Upside
BCAX Bicara Therapeutics	3.00	Buy	$31.86	235.00% Upside
CDXC ChromaDex	3.00	Buy	$9.03	∞ Upside
MOLN Molecular Partners	3.50	Strong Buy	$12.00	233.80% Upside

Current Analyst Ratings Breakdown

Latest MOLN, BCAX, AVBP, and CDXC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	AVBP ArriVent BioPharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$39.00 ➝ $44.00
6/24/2025	AVBP ArriVent BioPharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
5/23/2025	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$8.00
5/23/2025	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$30.00
5/20/2025	AVBP ArriVent BioPharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
5/16/2025	BCAX Bicara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $41.00
5/14/2025	AVBP ArriVent BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
4/17/2025	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underweight	$8.00
4/7/2025	BCAX Bicara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$45.00 ➝ $44.00
3/27/2025	BCAX Bicara Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$48.00
3/27/2025	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$31.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	$7.65 per share	N/A
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	$9.04 per share	N/A
CDXC ChromaDex	$99.60M	0.00	N/A	N/A	$0.38 per share	0.00
MOLN Molecular Partners	$5.65M	25.69	N/A	N/A	$3.99 per share	0.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$80.49M	-$3.77	N/A	N/A	N/A	N/A	-49.21%	-46.61%	8/13/2025 (Estimated)
BCAX Bicara Therapeutics	-$68M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	6/26/2025 (Estimated)
CDXC ChromaDex	-$4.94M	$0.10	787.29	0.00	N/A	1.62%	4.85%	2.70%	N/A
MOLN Molecular Partners	-$61.39M	-$1.92	N/A	N/A	N/A	-1,043.01%	-42.20%	-38.12%	8/25/2025 (Estimated)

Latest MOLN, BCAX, AVBP, and CDXC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	MOLN Molecular Partners	-$0.3855	-$0.50	-$0.1145	-$0.50	N/A	N/A
5/13/2025	Q1 2025	BCAX Bicara Therapeutics	-$0.40	-$0.68	-$0.28	-$0.68	N/A	N/A
5/12/2025	Q1 2025	AVBP ArriVent BioPharma	-$0.66	-$1.90	-$1.24	-$1.90	N/A	N/A
3/27/2025	Q4 2024	BCAX Bicara Therapeutics	-$0.31	-$0.39	-$0.08	-$0.39	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
CDXC ChromaDex	N/A	N/A	N/A	N/A	N/A
MOLN Molecular Partners	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	14.34	14.34
BCAX Bicara Therapeutics	N/A	24.62	24.62
CDXC ChromaDex	N/A	2.95	2.35
MOLN Molecular Partners	N/A	15.28	15.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
BCAX Bicara Therapeutics	N/A
CDXC ChromaDex	15.41%
MOLN Molecular Partners	26.55%

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	18.58%
BCAX Bicara Therapeutics	N/A
CDXC ChromaDex	9.64%
MOLN Molecular Partners	5.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	40	34.21 million	27.86 million	N/A
BCAX Bicara Therapeutics	32	54.54 million	N/A	N/A
CDXC ChromaDex	120	77.75 million	69.02 million	Optionable
MOLN Molecular Partners	180	40.38 million	37.98 million	Not Optionable

MOLN, BCAX, AVBP, and CDXC Headlines

Recent News About These Companies

Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025 - Morningstar

June 24 at 9:38 PM | morningstar.com

Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025

June 22 at 4:00 PM | globenewswire.com

Molecular Partners Reports Positive Phase 1/2a Data for MP0533 in Relapsed/Refractory AML at EHA Congress

June 12, 2025 | nasdaq.com

Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025

June 11, 2025 | uk.finance.yahoo.com

Molecular Partners to cut jobs, cash reach now anticipated to extend into 2028

June 10, 2025 | msn.com

Molecular Partners (NASDAQ:MOLN) Shares Up 2.2% - Time to Buy?

June 10, 2025 | marketbeat.com

Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway

June 10, 2025 | globenewswire.com

Molecular Partners to Present at Upcoming Investor Conferences

May 19, 2025 | globenewswire.com

Molecular Partners Reports Financial Results and Highlights from Q1 2025

May 16, 2025 | finance.yahoo.com

Molecular Partners presents new data on Radio-DARPin, Switch-DARPin programs

April 26, 2025 | markets.businessinsider.com

Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025

April 25, 2025 | globenewswire.com

Why Molecular Partners AG’s (MOLN) Stock Is Up 5.04%

April 17, 2025 | aaii.com

Molecular Partners Announces all Board Proposals Approved at Annual General Meeting

April 16, 2025 | globenewswire.com

Dendi and Molecular Lab Partners Announce Strategic Partnership to Empower Labs Nationwide

April 15, 2025 | tmcnet.com

Hedge funds owners may take dramatic actions as Molecular Partners AG's (VTX:MOLN) recent 15% drop adds to one-year losses

April 6, 2025 | finance.yahoo.com

Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher

April 3, 2025 | zacks.com

Why Molecular Partners AG’s (MOLN) Stock Is Up 9.28%

March 27, 2025 | aaii.com

Molecular Partners to hold three poster presentations at AACR 2025

March 25, 2025 | globenewswire.com

Molecular Partners Publishes Invitation to Annual General Meeting 2025

March 25, 2025 | globenewswire.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Molecular Partners (MOLN), United Therapeutics (UTHR) and Universal Health (UHS)

March 17, 2025 | markets.businessinsider.com

Molecular Partners (MOLN) Initiated with a Buy at LifeSci Capital

March 15, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN, BCAX, AVBP, and CDXC Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$23.11 +0.31 (+1.36%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$23.14 +0.03 (+0.11%)

As of 04:01 AM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Bicara Therapeutics NASDAQ:BCAX

$9.51 +0.33 (+3.59%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$9.74 +0.23 (+2.37%)

As of 04:12 AM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

ChromaDex NASDAQ:CDXC

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

Molecular Partners NASDAQ:MOLN

$3.60 -0.30 (-7.58%)

As of 06/24/2025 03:59 PM Eastern

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time